Weinert Letícia Schwerz, Ceolin Lucieli, Romitti Mírian, Camargo Eduardo Guimarães, Maia Ana Luiza
Thyroid Section, Endocrine Division, Hospital de Clínicas de Porto Alegre, RS, Brazil.
Arq Bras Endocrinol Metabol. 2012 Feb;56(1):67-71. doi: 10.1590/s0004-27302012000100010.
Resistance to thyroid hormone (RTH) is a rare autosomal dominant inherited disorder characterized by end-organ reduced sensitivity to thyroid hormone. This syndrome is caused by mutations of the thyroid hormone receptor (TR) β gene, and its clinical presentation is quite variable. Goiter is reported to be the most common finding. A close association of TRβ mutations with human cancers has become apparent, but the role of TRβ mutants in the carcinogenesis is still undefined. Moreover, higher TSH levels, described in RTH syndrome, are correlated with increased risk of thyroid malignancy, whereas TSH receptor stimulation is likely to be involved in tumor progression. We report here an illustrative case of a 29 year-old patient with RTH caused by a mutation in exon 9 (A317T) of TRβ gene, who presented multicentric papillary thyroid cancer. We review the literature on this uncommon feature, and discuss the potential role of this mutation on human tumorigenesis, as well as the challenges in patient follow-up.
甲状腺激素抵抗(RTH)是一种罕见的常染色体显性遗传性疾病,其特征是终末器官对甲状腺激素的敏感性降低。该综合征由甲状腺激素受体(TR)β基因突变引起,其临床表现差异很大。据报道,甲状腺肿是最常见的表现。TRβ突变与人类癌症之间的密切关联已变得明显,但TRβ突变体在致癌过程中的作用仍不明确。此外,RTH综合征中描述的较高促甲状腺激素(TSH)水平与甲状腺恶性肿瘤风险增加相关,而TSH受体刺激可能参与肿瘤进展。我们在此报告一例29岁因TRβ基因外显子9(A317T)突变导致RTH的患者,该患者患有多中心乳头状甲状腺癌。我们回顾了关于这一罕见特征的文献,并讨论了该突变在人类肿瘤发生中的潜在作用以及患者随访中的挑战。